Published in Pediatr Infect Dis J on June 01, 2011
Viral acute lower respiratory infections impair CD8+ T cells through PD-1. J Clin Invest (2012) 1.31
Epidemiology of hospitalization for acute bronchiolitis in children: differences between RSV and non-RSV bronchiolitis. Eur J Clin Microbiol Infect Dis (2012) 1.25
Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis. Pediatr Infect Dis J (2014) 1.21
Respiratory syncytial virus hospitalization risk in the second year of life by specific congenital heart disease diagnoses. PLoS One (2017) 1.05
Respiratory syncytial virus-associated mortality in hospitalized infants and young children. Pediatrics (2014) 1.02
Environmental drivers of the spatiotemporal dynamics of respiratory syncytial virus in the United States. PLoS Pathog (2015) 0.98
Challenges and opportunities in developing respiratory syncytial virus therapeutics. J Infect Dis (2015) 0.96
Respiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005-2012) compared to other international registries. Clin Dev Immunol (2013) 0.93
Surveillance for hospitalized acute respiratory infection in Guatemala. PLoS One (2013) 0.91
Trends in Respiratory Syncytial Virus and Bronchiolitis Hospitalization Rates in High-Risk Infants in a United States Nationally Representative Database, 1997-2012. PLoS One (2016) 0.90
Hospitalizations for respiratory syncytial virus bronchiolitis in preterm infants at <33 weeks gestation without bronchopulmonary dysplasia: the CASTOR study. Epidemiol Infect (2012) 0.88
Respiratory Syncytial Virus Hospitalizations in Healthy Preterm Infants: Systematic Review. Pediatr Infect Dis J (2016) 0.87
(S)-N-(2,5-Dimethylphenyl)-1-(quinoline-8-ylsulfonyl)pyrrolidine-2-carboxamide as a small molecule inhibitor probe for the study of respiratory syncytial virus infection. J Med Chem (2012) 0.86
Probiotics in respiratory virus infections. Eur J Clin Microbiol Infect Dis (2014) 0.85
Impact of rhinoviruses on pediatric community-acquired pneumonia. Eur J Clin Microbiol Infect Dis (2011) 0.85
Respiratory syncytial virus persistence in macrophages alters the profile of cellular gene expression. Viruses (2012) 0.84
Molecular epidemiology of respiratory syncytial virus transmission in childcare. J Clin Virol (2013) 0.84
A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS). Eur J Clin Microbiol Infect Dis (2012) 0.82
Predictors of severity and mortality in children hospitalized with respiratory syncytial virus infection in a tropical region. Pediatr Pulmonol (2013) 0.82
The impact of influenza and respiratory syncytial virus on hospitalizations for lower respiratory tract infections in young children: Slovenia, 2006-2011. Influenza Other Respir Viruses (2013) 0.81
Respiratory syncytial virus-associated hospitalizations in pre-mature infants in Lima, Peru. Am J Trop Med Hyg (2014) 0.78
A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation. BMC Res Notes (2012) 0.78
Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in preterm infants: determination of the ideal target population for prophylaxis. Eur J Clin Microbiol Infect Dis (2017) 0.75
Burden of Severe Respiratory Syncytial Virus Disease Among 33-35 Week Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons. Pediatr Infect Dis J (2016) 0.75
Immunogenicity of RSV F DNA Vaccine in BALB/c Mice. Adv Virol (2016) 0.75
Characterization of Pre-F-GCN4t, a modified human respiratory syncytial virus fusion protein stabilized in a non-cleaved pre-fusion conformation. J Virol (2017) 0.75
Insurance Status and the Risk of Severe Respiratory Syncytial Virus Disease in United States Preterm Infants Born at 32-35 Weeks Gestational Age. Open Forum Infect Dis (2016) 0.75
Evaluation of recent New Vaccine Surveillance Network data regarding respiratory syncytial virus hospitalization rates in US preterm infants. Hum Vaccin Immunother (2016) 0.75
Transplacental transfer of maternal respiratory syncytial virus (RSV) antibody and protection against RSV disease in infants in rural Nepal. J Clin Virol (2017) 0.75
Effectiveness of Palivizumab in High-risk Infants and Children: A Propensity Score Weighted Regression Analysis. Pediatr Infect Dis J (2017) 0.75
Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA (2003) 31.71
A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med (2003) 29.55
Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science (2003) 18.34
A distinct lineage of influenza A virus from bats. Proc Natl Acad Sci U S A (2012) 6.27
Virological features and clinical manifestations associated with human metapneumovirus: a new paramyxovirus responsible for acute respiratory-tract infections in all age groups. J Infect Dis (2002) 6.09
Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. JAMA (2005) 5.84
Characterization of human metapneumoviruses isolated from patients in North America. J Infect Dis (2002) 5.64
Human metapneumovirus infections in young and elderly adults. J Infect Dis (2003) 4.91
Guidelines for preventing health-care--associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep (2004) 3.84
Rhinovirus-associated hospitalizations in young children. J Infect Dis (2007) 3.35
Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis (2012) 3.35
Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci U S A (2004) 3.23
In search of encephalitis etiologies: diagnostic challenges in the California Encephalitis Project, 1998-2000. Clin Infect Dis (2003) 2.99
Identification of a novel astrovirus (astrovirus VA1) associated with an outbreak of acute gastroenteritis. J Virol (2009) 2.96
Real-time reverse transcription-polymerase chain reaction assay for SARS-associated coronavirus. Emerg Infect Dis (2004) 2.88
Prevalence of viral respiratory tract infections in children with asthma. J Allergy Clin Immunol (2006) 2.67
Human bocavirus: a novel parvovirus epidemiologically associated with pneumonia requiring hospitalization in Thailand. J Infect Dis (2007) 2.65
Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep (2003) 2.53
Human metapneumovirus infection among children hospitalized with acute respiratory illness. Emerg Infect Dis (2004) 2.35
Viral respiratory infections in hospitalized and community control children in Alaska. J Med Virol (2010) 2.29
Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006. Pediatr Infect Dis J (2012) 2.12
Sensitive and broadly reactive reverse transcription-PCR assays to detect novel paramyxoviruses. J Clin Microbiol (2008) 2.10
Lower respiratory tract infections among american Indian and Alaska Native children and the general population of U.S. Children. Pediatr Infect Dis J (2005) 2.07
Application of TaqMan low-density arrays for simultaneous detection of multiple respiratory pathogens. J Clin Microbiol (2011) 2.07
Detection of novel SARS-like and other coronaviruses in bats from Kenya. Emerg Infect Dis (2009) 2.04
Sequence analysis of the N, P, M and F genes of Canadian human metapneumovirus strains. Virus Res (2003) 1.96
Human rhinovirus species associated with hospitalizations for acute respiratory illness in young US children. J Infect Dis (2011) 1.93
Burden of encephalitis-associated hospitalizations in the United States, 1988-1997. Clin Infect Dis (2002) 1.92
Novel human rhinoviruses and exacerbation of asthma in children. Emerg Infect Dis (2008) 1.87
Respiratory syncytial virus hospitalizations among American Indian and Alaska Native infants and the general United States infant population. Pediatrics (2004) 1.83
GeneScan reverse transcription-PCR assay for detection of six common respiratory viruses in young children hospitalized with acute respiratory illness. J Clin Microbiol (2003) 1.83
Respiratory syncytial virus activates innate immunity through Toll-like receptor 2. J Virol (2008) 1.80
Outbreak of severe respiratory disease associated with emergent human adenovirus serotype 14 at a US air force training facility in 2007. J Infect Dis (2009) 1.78
Molecular epidemiology of adenovirus type 7 in the United States, 1966-2000. Emerg Infect Dis (2002) 1.78
Substantial variability in community respiratory syncytial virus season timing. Pediatr Infect Dis J (2003) 1.71
Laboratory diagnosis of four recent sporadic cases of community-acquired SARS, Guangdong Province, China. Emerg Infect Dis (2004) 1.65
Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses. J Immunol (2006) 1.45
Sequence polymorphism of the predicted human metapneumovirus G glycoprotein. J Gen Virol (2004) 1.44
Risk factors for bronchiolitis-associated deaths among infants in the United States. Pediatr Infect Dis J (2003) 1.35
Two outbreaks of severe respiratory disease in nursing homes associated with rhinovirus. J Am Geriatr Soc (2006) 1.32
Variation in timing of respiratory syncytial virus outbreaks: lessons from national surveillance. Pediatr Infect Dis J (2007) 1.30
Seasonal trends of human parainfluenza viral infections: United States, 1990-2004. Clin Infect Dis (2006) 1.30
Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway. PLoS Pathog (2008) 1.27
Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice. J Virol (2009) 1.23
Infectious disease hospitalizations among American Indian and Alaska native infants. Pediatrics (2003) 1.23
Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice. J Infect Dis (2009) 1.22
Multiplex assay for detection of strain-specific antibodies against the two variable regions of the G protein of respiratory syncytial virus. Clin Diagn Lab Immunol (2002) 1.22
Clinical and epidemiologic features of respiratory syncytial virus. Curr Top Microbiol Immunol (2013) 1.20
The G glycoprotein of respiratory syncytial virus depresses respiratory rates through the CX3C motif and substance P. J Virol (2003) 1.20
Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients. J Immunol (2009) 1.14
Viral meningitis-associated hospitalizations in the United States, 1988-1999. Neuroepidemiology (2003) 1.13
Use of respiratory syncytial virus surveillance data to optimize the timing of immunoprophylaxis. Pediatrics (2010) 1.08
Outbreak of pneumonia associated with emergent human adenovirus serotype 14--Southeast Alaska, 2008. J Infect Dis (2010) 1.08
Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice. J Gen Virol (2009) 1.07
Severe acute respiratory syndrome: review and lessons of the 2003 outbreak. Int J Epidemiol (2004) 1.04
Refractory status epilepticus in suspect encephalitis. Neurocrit Care (2008) 1.04
SARS surveillance during emergency public health response, United States, March-July 2003. Emerg Infect Dis (2004) 1.03
Severe bronchiolitis and respiratory syncytial virus among young children in Hawaii. Pediatr Infect Dis J (2007) 0.99
Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins. J Virol Methods (2005) 0.99
Peripheral blood mononuclear cells from infants hospitalized because of respiratory syncytial virus infection express T helper-1 and T helper-2 cytokines and CC chemokine messenger RNA. J Infect Dis (2002) 0.98
Recombinant protein-based assays for detection of antibodies to severe acute respiratory syndrome coronavirus spike and nucleocapsid proteins. Clin Vaccine Immunol (2007) 0.98
Cytochrome P450 1B1 contributes to renal dysfunction and damage caused by angiotensin II in mice. Hypertension (2011) 0.97
Kawasaki disease and human coronavirus. J Infect Dis (2005) 0.97
Challenges and opportunities for respiratory syncytial virus vaccines. Curr Top Microbiol Immunol (2013) 0.96
SARS-coronavirus replication in human peripheral monocytes/macrophages. Virus Res (2005) 0.96
A respiratory syncytial virus (RSV) anti-G protein F(ab')2 monoclonal antibody suppresses mucous production and breathing effort in RSV rA2-line19F-infected BALB/c mice. J Virol (2013) 0.95
Neutralizing anti-F glycoprotein and anti-substance P antibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection. J Virol (2002) 0.95
Evaluation of the Calu-3 cell line as a model of in vitro respiratory syncytial virus infection. J Virol Methods (2011) 0.94
Outpatient and hospital visits associated with otitis media among American Indian and Alaska native children younger than 5 years. Pediatrics (2002) 0.94
Challenges to evaluating respiratory syncytial virus mortality in Bangladesh, 2004-2008. PLoS One (2013) 0.93
Human bocavirus: a new viral pathogen. Clin Infect Dis (2007) 0.93
Respiratory syncytial virus G protein CX3C motif impairs human airway epithelial and immune cell responses. J Virol (2013) 0.92
Direct sequencing of SARS-coronavirus S and N genes from clinical specimens shows limited variation. J Infect Dis (2004) 0.92
Persistent parvovirus B19 infection without the development of chronic anemia in HIV-infected and -uninfected children: the Women and Infants Transmission Study. J Infect Dis (2004) 0.91
Severe acute respiratory syndrome coronavirus on hospital surfaces. Clin Infect Dis (2004) 0.89
Health care transmission of a newly emergent adenovirus serotype in health care personnel at a military hospital in Texas, 2007. J Infect Dis (2009) 0.89
Prior airway exposure to allergen increases virus-induced airway hyperresponsiveness. J Allergy Clin Immunol (2003) 0.88
Substance P receptor expression on lymphocytes is associated with the immune response to respiratory syncytial virus infection. J Neuroimmunol (2002) 0.88
Involvement of cytochrome P-450 1B1 in renal dysfunction, injury, and inflammation associated with angiotensin II-induced hypertension in rats. Am J Physiol Renal Physiol (2011) 0.88
Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease. PLoS One (2013) 0.87
SARS-associated coronavirus transmission, United States. Emerg Infect Dis (2004) 0.87
Identification of adenoviruses in fecal specimens from wild chimpanzees (Pan trogylodytes schweinfurthii) in western Tanzania. Am J Trop Med Hyg (2010) 0.87
Emerging human coronaviruses--disease potential and preparedness. N Engl J Med (2012) 0.86
Real-time detection of virus particles and viral protein expression with two-color nanoparticle probes. J Virol (2005) 0.85
Cytochrome P450 1B1 gene disruption minimizes deoxycorticosterone acetate-salt-induced hypertension and associated cardiac dysfunction and renal damage in mice. Hypertension (2012) 0.85
Application of proteomics methods for pathogen discovery. J Virol Methods (2009) 0.84
Respiratory syncytial virus and Staphylococcus aureus coinfection in children hospitalized with pneumonia. Pediatr Infect Dis J (2010) 0.84
CD40 ligand (CD154) improves the durability of respiratory syncytial virus DNA vaccination in BALB/c mice. Vaccine (2003) 0.84
Annual variation in respiratory syncytial virus season and decisions regarding immunoprophylaxis with palivizumab. Pediatrics (2004) 0.83
Response to rhinovirus infection by human airway epithelial cells and peripheral blood mononuclear cells in an in vitro two-chamber tissue culture system. PLoS One (2013) 0.83
Genomic characterization of seven distinct bat coronaviruses in Kenya. Virus Res (2012) 0.82
A Vision-Based Respiration Monitoring System for Passive Airway Resistance Estimation. IEEE Trans Biomed Eng (2015) 0.81
Pulmonary delivery of respiratory syncytial virus DNA vaccines using macroaggregated albumin particles. Vaccine (2004) 0.81
Combination therapy using monoclonal antibodies against respiratory syncytial virus (RSV) G glycoprotein protects from RSV disease in BALB/c mice. PLoS One (2012) 0.80
Eighteen Years of Respiratory Syncytial Virus Surveillance: Changes in Seasonality and Hospitalization Rates in Southwestern Alaska Native Children. Pediatr Infect Dis J (2015) 0.78
Coronavirus antibodies in bat biologists. Emerg Infect Dis (2008) 0.77
Development of a recombinant truncated nucleocapsid protein based immunoassay for detection of antibodies against human coronavirus OC43. J Virol Methods (2011) 0.76
A passive quantitative measurement of airway resistance using depth data. Conf Proc IEEE Eng Med Biol Soc (2014) 0.75